- Clearmind Medicine Inc. (CMND) and SciSparc Ltd. announce a collaboration that yields a new provisional patent application for binge behaviours
- Pre-clinical trials based on proprietary combination demonstrate a significant suppressive effect on alcohol consumption
- Initial results of the pre-clinical mice the study showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg
- The mice were provided with 20 per cent alcohol solution for 24 hours three times a week for seven weeks
- The alcohol consumption was measured by weighing the alcohol bottles before and after, and water consumption was measured similarly in parallel
- Clearmind Medicine Inc. (CMND) is down 3.90 per cent, trading at C$0.37 at 11:22 am ET
Clearmind Medicine (CMND) filed a provisional patent application resulting from its recently launched collaboration with SciSparc Ltd. (NASDAQ: SPRC).
The patent application is related to a psychedelic combination therapy to treat binge behaviours.
SciSparc is a specialty clinical-stage pharmaceutical company focusing on developing therapies to treat disorders of the central nervous system.
The patent application combines Clearmind’s MEAI, a novel proprietary psychedelic treatment for addictions and binge behaviours, with SciSparc’s CannAmide™.
The patent application followed a successful pre-clinical study that showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with an additional significant impact for the CannAmide™ treatment at the lower, sub-effective MEAI dose.
“Clearmind continues to expand its IP portfolio and pave its way as the holder of the most significant patent portfolio in the industry,” said Dr. Adi Zuloff- Shani, Clearmind’s Chief Executive Officer.
“Clearmind’s patent portfolio, built around technologies we developed, is unique in the psychedelic field. This patent application results from the successful pre-clinical results we announced in March, making a wider collaboration with SciSparc a natural progression,” added Zuloff-Shani.
The pre-clinical mice study showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p<0.01) compared to consumption before treatment.
Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg, again compared to consumption before treatment.
The mice were provided with 20 per cent alcohol solution for 24 hours three times a week for seven weeks and were treated every day with MEAI or the combination of MEAI and CannAmide™ during the last two weeks of alcohol treatment.
The alcohol consumption was measured by weighing the alcohol bottles before and after, and water consumption was measured similarly in parallel.
Clearmind is a new biotech company focused on discovering and developing novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
The Israeli- Canadian company holds several patents, among others, for the non-hallucinogenic compound MEAI. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding acquiring additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND,” the Frankfurt Stock Exchange under the symbol “CWYO,” and on the OTC pink under the symbol “CMNDF.”
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals—disorder and status epilepticus.
Clearmind Medicine Inc. (CMND) is down 3.90 per cent, trading at C$0.37 at 11:22 am ET.
